Quest Diagnostics Incorporated

Equities

DGX

US74834L1008

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
134.3 ^USD	-0.86%		+4.53%	-2.63%

Apr. 25	Labcorp beats quarterly estimates on strong testing demand	RE
Apr. 24	Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155	MT

Quest Diagnostics Incorporated acquired Assets of Lenco Diagnostic Laboratories, Inc. for approximately $110 million.

February 21, 2024

Quest Diagnostics Incorporated (NYSE:DGX) acquired Assets of Lenco Diagnostic Laboratories, Inc. for approximately $110 million on February 12, 2024. Michael Darby of Dechert LLP acted as legal advisor to Quest.

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Assets of Lenco Diagnostic Laboratories, Inc. on February 12, 2024.

Latest news about Quest Diagnostics Incorporated

Labcorp beats quarterly estimates on strong testing demand	Apr. 25	RE
Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155	Apr. 24	MT
UBS Adjusts Price Target on Quest Diagnostics to $146 From $139, Maintains Neutral Rating	Apr. 24	MT
Barclays Raises Quest Diagnostics' Price Target to $144 From $138	Apr. 24	MT
Deutsche Bank Adjusts Quest Diagnostics Price Target to $136 From $125, Maintains Hold Rating	Apr. 24	MT
Mizuho Adjusts Quest Diagnostics' Price Target to $155 From $150	Apr. 24	MT
Citigroup Adjusts Quest Diagnostics Price Target to $145 From $135	Apr. 24	MT
Leerink Partners Adjusts Quest Diagnostics Price Target to $141 From $135	Apr. 24	MT
Truist Raises Price Target on Quest Diagnostics to $150 From $145, Cites 'Strong Start' to 2024, Keeps Hold Rating	Apr. 24	MT
Evercore ISI Raises Quest Diagnostics Price Target to $145 from $140	Apr. 23	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Apr. 23	MT
Transcript : Quest Diagnostics Incorporated, Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Quest Diagnostics Posts Flat Q1 Adjusted Earnings, Revenue Rises; 2024 Earnings, Revenue Guidance Raised	Apr. 23	MT
Earnings Flash (DGX) QUEST DIAGNOSTICS Reports Q1 Revenue $2.37B, vs. Street Est of $2.29B	Apr. 23	MT
Earnings Flash (DGX) QUEST DIAGNOSTICS Posts Q1 EPS $2.04, vs. Street Est of $1.86	Apr. 23	MT
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024	Apr. 23	CI
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats	Apr. 23	RE
Quest Diagnostics Launches New Test to Help Assess Alzheimer's Disease Risk	Apr. 22	MT
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease	Apr. 22	CI
John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission	Apr. 11	CI
Quest Diagnostics Receives Shareholder Proposal from John Chevedden	Apr. 05	CI
Quest Collaborating With Broad Clinical Labs to Assess Whole Genome Sequencing Test for Developmental Delay Disorders	Apr. 02	MT
Quest Diagnostics Receives Shareholder Proposal from John Chevedden	Mar. 25	CI
Transcript : Quest Diagnostics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM	Mar. 13

Chart Quest Diagnostics Incorporated

Duration

Period

More charts

Company Profile

Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows: - testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services; - other (2.7%).

Sector

Healthcare Facilities & Services

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Quest Diagnostics Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

134.3 USD

Average target price

146 USD

Spread / Average Target

+8.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
EUROFINS SCIENTIFIC SE	-3.97%	11.66B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
PURE HEALTH HOLDING	-31.75%	11.77B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services